Premium
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity
Author(s) -
Smith S. R.,
Fujioka K.,
Gupta A. K.,
Billes S. K.,
Burns C.,
Kim D.,
Dunayevich E.,
Greenway F. L.
Publication year - 2013
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12095
Subject(s) - bupropion , naltrexone , placebo , medicine , weight loss , anesthesia , pharmacology , obesity , smoking cessation , antagonist , receptor , alternative medicine , pathology
The effects of combination naltrexone/bupropion therapy on body composition and visceral adipose tissue ( VAT ) mass were examined in a subset (n = 107) of obese subjects from a Phase 2 trial that compared the efficacy and safety of placebo, naltrexone monotherapy, bupropion monotherapy or one of three naltrexone/bupropion dose combinations for 24 weeks. Body composition data were obtained using dual‐energy X‐ray absorptiometry and computed tomography. Eighty subjects completed the substudy. Naltrexone/bupropion resulted in weight loss and a greater reduction in body fat (−14.0 ± 1.3%) than placebo (−4.0 ± 2.0%), naltrexone monotherapy (−3.2 ± 2.5%) and bupropion monotherapy (−4.1 ± 2.9%; all p < 0.01). Reduction in VAT mass was also greater with naltrexone/bupropion (−15.0 ± 1.8%) than placebo (−4.6 ± 2.7%), naltrexone monotherapy (−0.1 ± 3.5%) and bupropion monotherapy (−2.3 ± 4.2%; all p < 0.01). Reductions in body fat and VAT mass with naltrexone/bupropion were proportional with weight loss. Weight loss with naltrexone/bupropion was not associated with a greater relative reduction in lean mass than placebo or the monotherapies.